作者

Judith Krens

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More

Dr. Nora E. Wessendorf, LL.M. (Washington)

高级律师

Read More
作者

Judith Krens

合伙人

Read More

Matthew Royle, Ph.D.

合伙人

Read More

Dr. Nora E. Wessendorf, LL.M. (Washington)

高级律师

Read More

2020年11月25日 | 59:21

Biologics and biosimilars litigation update

Catch up on the third and final webinar in our 2020 series on decisions in the United States and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 3 focuses on recent key developments in the United States and Europe, including:

  • Recent decisions and developments in the United States which may impact biologics and biosimilars, including Arthrex v Smith & Nephew, AAM v Becerra, and GSK v Teva.
  • Recent decisions and developments in Europe, including the Santen CJEU decision, enforcement of personalised medicine claims, and the UK’s guidelines for biosimilars post Brexit. 
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
酒店与休闲

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

2020年7月27日
QUICK READ

作者

点击此处了解更多
woman-with-scientific-model
酒店与休闲

Everything biologic and biosimilar in-house counsel need to know about COVID-19

2020年4月29日

作者

点击此处了解更多
酒店与休闲

Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations

2019年12月17日

作者 Matthew Royle, Ph.D.

点击此处了解更多

相关活动